# A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

> **NCT05571839** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 41 (actual)

## Conditions studied

- Cutaneous Melanoma
- Non-small Cell Lung Cancer
- Colorectal Neoplasms
- Pancreatic Neoplasms
- Mesothelioma

## Interventions

- **DRUG:** PF-08046049

## Key facts

- **NCT ID:** NCT05571839
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-03
- **Primary completion:** 2026-06-06
- **Final completion:** 2026-06-06
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05571839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05571839, "A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05571839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*